can-19

2,2-Dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl 4-methylbenzenesulfonate 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T64637。

Tocilizumab （Anti-Human IL6R) 是抗人白细胞介素-6 受体 (IL-6R) 的中和抗体，能够阻碍 IL-6 与 IL-6R 的结合，进而抑制经典和反式信号。可用于研究类风湿性关节炎，并且被建议作为治疗重症 COVID-19 的可能药物。

Deferoxamine（Desferrioxamine B） 是一种铁螯合剂 (结合 Fe(III) 和许多其他金属阳离子)，可抑制神经元病变，可用于改减少铁在组织中的积累和沉积，可通过抑制创伤性脑损伤后的铁死亡和神经炎症来改善神经功能障碍。Desferrioxamin-B 具有抗氧化、抗增殖、抗肿瘤活性，可诱导 HIF-1α 产生，诱导癌细胞凋亡和自噬。Desferrioxamin-B 可用于治疗急性铁中毒和与 COVID-19 相关疾病。

Tirzepatide (LY3298176) Acetate(2023788-19-2 free base) 是一种新分子，能够通过结合葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体的双重激动作用来控制血糖水平。[3]

Nirmatrelvir (PF-07321332) 是一种 SARS-CoV 3CLPRO 抑制剂，一种胰蛋白酶样蛋白酶抑制剂，具有有效性和口服活性。Nirmatrelvir 对 SARS-CoV-2 病毒有针对性，可研究 COVID-19。

Aleglitazar (R1439) 是一种高效的 PPARα γ 双重激动剂，对人 PPARα 和 PPARγ 作用的 IC50 分别为 38 nM 和 19 nM。Aleglitazar 可用于 II 型糖尿病的研究。

SARS-CoV-2 Mpro-IN-2 是一种选择性的SARS-CoV-2M pro抑制剂，IC50 值为 0.40 μM。SARS-CoV-2 Mpro-IN-2 具有良好的抗病毒活性，可用于研究 COVID-19。

BI7273 是一种选择性的可细胞透过BRD9抑制剂，IC50和Kd 分别为 19 和 0.75 nM。它对 BRD7 的作用较强，IC50和Kd 值分别为 117 和 0.3 nM。

Molnupiravir (EIDD-2801) 是核糖核苷类似物 EIDD-1931 的异丙酯前体药物，具有口服生物利用度。Molnupiravir 可用于 COVID-19 ，季节性和流行性流感的研究，对多种冠状病毒和流感病毒具有广谱的抗病毒活性，例如，SARS-CoV-2，MERS-CoV，SARS-CoV。

Sitagliptin (MK0431) 是一种有效的 DPP4抑制剂，在 Caco-2 细胞中，IC50值为 19 nM。它是一种新型口服降糖药，可单独使用或与二甲双胍或噻唑烷二酮联合用于治疗 2 型糖尿病。

Talabostat (PT100, Val-boroPro) is a potent, nonselective and orally available dipeptidyl peptidase IV (DPP-IV) inhibitor with a Ki of 0.18 nM. Talabostat is a nonselective DPP-IV inhibitor, inhibiting DPP8 9, FAP, DPP2 and some other DASH family enzymes essentially as potently as it inhibits DPP-IV[1]. Talabostat stimulates the immune system by triggering a proinflammatory form of cell death in monocytes and macrophages known as pyroptosis. The inhibition of two serine proteases, DPP8 and DPP9, activates the proprotein form of caspase-1 independent of the inflammasome adaptor ASC[2]. Talabostat competitively inhibits the dipeptidyl peptidase (DPP) activity of FAP and CD26 DPP-IV, and there is a high-affinity interaction with the catalytic site due to the formation of a complex between Ser630 624 and the boron of talabostat[3]. Talabostat can stimulate immune responses against tumors involving both the innate and adaptive branches of the immune system. In WEHI 164 fibrosarcoma and EL4 and A20 2J lymphoma models, PT-100 causes regression and rejection of tumors. The antitumor effect appears to involve tumor-specific CTL and protective immunological memory. Talabostat treatment of WEHI 164-inoculated mice increases mRNA expression of cytokines and chemokines known to promote T-cell priming and chemoattraction of T cells and innate effector cells[3]. Talabostat treated mice show significant less fibrosis and FAP expression is reduced. Upon PT100 treatment, significant differences in the MMP-12, MIP-1α, and MCP-3 mRNA expression levels in the lungs are also observed. Treatment with PT100 in this murine model of pulmonary fibrosis has an anti-fibro-proliferative effect and increases macrophage activation[4]. [1]. Connolly BA, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potencyand in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13. [2]. Okondo MC, et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017 Jan;13(1):46-53. [3]. Adams S, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004 Aug 1;64(15):5471-80. [4]. Egger C, et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol. 2017 Aug 15;809:64-72.

Eurifoloid Q 是一种天然化合物，可作为天然产物对照品，其 CAS 号为 1629153-19-0。

Acephate-d3 (acetyl-d3) 是 Acephate 的氘代化合物。Acephate 的 CAS 号为 30560-19-1。Acephate 是能产生胆碱毒性的抗胆碱酯酶杀虫剂。它能够有效抑制蟑螂的AChE，但对大鼠 AChE 的抑制作用较弱。

NHS-MMAF 是 NHS 修饰的 MMAF，可用于生命科学相关研究，其 CAS 号为 1404073-19-3。

Vonoprazan-d4 是 Vonoprazan 的氘代化合物。Vonoprazan 的 CAS 号为 881681-00-1。Vonoprazan 是一种质子泵抑制剂，是口服活性钾竞争性酸阻断剂，有抗分泌作用。在 pH 为 6.5 时，它抑制猪胃微粒体中的 H+,K+-ATPase 酶活性，IC50值为 19 nM。它可用于研究胃酸相关疾病。

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg ml) and Kurono (MIC: 0.0005 μg ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1 2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg kg to 2.5 mg kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

7-Methylguanosine 5’-diphosphate (7-Methyl-GDP) sodium, a cap analog, can be used in the synthesis of mRNA cap analogues[1]. 7-Methylguanosine 5’-diphosphate sodium inhibits binding of eukaryotic initiation factors to reovirus capped mRNA and complex formation involving uncapped mRNA or 18 S rRNA[1].T. brucei mRNA decapping enzyme (TbDcp2) that cleaves 7-Methylguanosine 5’-diphosphate sodium from capped RNA to generate pRNA, a substrate for TbCe1[2]. [1]. Sonenberg N, et al. Nonspecific effect of m7GMP on protein-RNA interactions. J Biol Chem. 1978;253(19):6630-6632.[2]. Ignatochkina AV, et al. The messenger RNA decapping and recapping pathway in Trypanosoma. Proc Natl Acad Sci U S A. 2015;112(22):6967-6972.

CYP4A11 CYP4F2-IN-1 是一种高效的小分子细胞色素 P450 (CYP) 4A11 和 CYP4F2 抑制剂，对P450 (CYP) 4A11 的 IC50 值为 19 nM，对 CYP4F2 的 IC50 值为 17 nM。CYP4A11 CYP4F2-IN-1 可用于研究肾脏疾病和心脑血管疾病。

(±)19(20)-EpDTE is an oxylipin and an oxidative metabolite of docosapentaenoic acid . It is formed via cytochrome P450 (CYP) metabolism of DPA and can be further metabolized to (±)19(20)-DiHDTE by epoxide hydrolase.

Deltorphin II is a peptide agonist of δ2-opioid receptors.1,2It is selective for δ-opioid receptors over μ- and κ-opioid receptors in radioligand bindings assays (Kis = 0.0033, >1, and >1 μM, respectively) and induces [35S]GTPγS binding in mouse brain membrane preparations (EC50= 0.034 μM). Deltorphin II (0.12 mg kg) decreases the infarction zone:risk zone ratio in a rat model of myocardial ischemia-reperfusion injury induced by coronary occlusion, an effect that can be reversed by the δ2-opioid receptor antagonist naltriben but not the δ1-opioid receptor antagonist BNTX.3Intrathecal administration of deltorphin II (15 μg animal) increases latency to withdraw in the paw pressure and tail-flick tests in rats.4 1.Raynor, K., Kong, H., Chen, Y., et al.Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptorsMol. Pharm.45(2)330-334(1994) 2.Scherrer, G., Befort, K., Contet, C., et al.The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: A parallel study of mu, delta and combinatorial opioid receptor knockout miceEur. J. Neurosci.19(8)2239-2248(2004) 3.Maslov, L.N., Barzakh, E.I., Krylatov, A.V., et al.Opioid peptide deltorphin II simulates the cardioprotective effect of ischemic preconditioning: role of δ2-opioid receptors, protein kinase C, and KATP channelsBull. Exp. Biol. Med.149(5)591-593(2010) 4.Labuz, D., Toth, G., Machelska, H., et al.Antinociceptive effects of isoleucine derivatives of deltorphin I and deltorphin II in rat spinal cord: A search for selectivity of delta receptor subtypesNeuropeptides32(6)511-517(1998)

Steroid sulfatase 17β-HSD1-IN-3 (compound 19) 是一种双重的类固醇硫酸酯酶 (STS) 和 17β-羟基类固醇脱氢酶 1 型 (17β HSD1) 抑制剂。Steroid sulfatase 17β-HSD1-IN-3 对 hSTS 的活性具有不可逆的抑制作用 (IC50: 27 nM)。Steroid sulfatase 17β-HSD1-IN-3 能够用于研究子宫内膜异位症及其他雌激素依赖性疾病。

Protein Kinase C (19-35) Peptide 是PKC 假底物抑制剂 区域。Protein Kinase C (19-35) Peptide 阻断PKC 激酶结构域的底物结合位点，使PKC 的细胞质形式失活。

Nezulcitinib (TD-0903) 是一种吸入的、肺选择性的 pan-Janus kinase (JAK) 抑制剂，能够用于研究 COVID-19 相关急性肺损伤及氧合受损。

KY19382 (2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-Ky19382) 是一种具有口服活性的 CXXC5-DVL (IC50:19 nM) 和 GSK3β (IC50:10 nM) 的双重抑制剂。它通过对 CXXC5-DVL 相互作用和 GSK3β 活性的抑制作用激活 Wnt β-catenin 信号传导。它可用于高脂饮食诱发的代谢性疾病的研究。